Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab for Early Relapse of Follicular Lymphoma (MERLIN)
NCT05849857Phase 2Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Sep 2023
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab in follicular lymphoma (FL), sponsored by Oslo University Hospital. Primary endpoint: Progression-Free Survival at 4 years. Started Sep 2023; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05849857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849857.